Active substance
Results for the substance ipilimumab
2 results
About this active substance
Ipilimumab is a monoclonal antibody used for the treatment of certain types of cancer, including metastatic melanoma. It works by blocking the CTLA-4 protein, thereby stimulating the immune system to attack cancer cells.
The medication is administered intravenously, according to a schedule determined by a doctor. It is important to monitor the patient for adverse reactions during treatment.
Side effects may include fatigue, diarrhea, skin rashes, or inflammation of organs such as colitis or hepatitis. In rare cases, severe immune-related reactions may occur.
Ipilimumab is not recommended for patients with hypersensitivity to this medication or severe autoimmune conditions.
The medication is administered intravenously, according to a schedule determined by a doctor. It is important to monitor the patient for adverse reactions during treatment.
Side effects may include fatigue, diarrhea, skin rashes, or inflammation of organs such as colitis or hepatitis. In rare cases, severe immune-related reactions may occur.
Ipilimumab is not recommended for patients with hypersensitivity to this medication or severe autoimmune conditions.